<DOC>
	<DOCNO>NCT02850016</DOCNO>
	<brief_summary>The aim protocol evaluate effect romidepsin plus 3BNC117 romidepsin alone delay prevent viral rebound ART-treated HIV-1-infected individual analytical interruption ART .</brief_summary>
	<brief_title>Romidepsin Plus 3BNC117 Phase 2a Study</brief_title>
	<detailed_description>This randomize interventional phase 2a trial 3BNC117 romidepsin human immunodeficiency ( HIV-1 ) infect patient ART , conduct multi-center study Department Infectious Diseases , Aarhus University Hospital , Denmark , Rockefeller University Hospital , USA , University Hospital Cologne , Germany . Participants randomize 1:1 non-blinded fashion receive one two regimen : A ) Two treatment cycle consist one 3BNC117 infusion ( 30mg/kg ) + three romidepsin infusion ( 5mg/m2 ) ; B ) Two treatment cycle consist three romidepsin infusion ( 5mg/m2 ) . ART discontinue 16 week start second treatment cycle ( analytical treatment interruption , ATI ) subject monitored weekly safety viral rebound . The targeted enrollment 30 subject ( 15 per arm ) . Leukapheresis perform two treatment cycle guarantee sufficient material investigate change reservoir intervention . The following criterion require resumption ART : - CD4+ T cell-count &lt; 350 cells/mm³ ( confirm repeat measurement ) - 2 consecutive plasma HIV-1 RNA measurement ≥ 200 copies/mL setpoint viremia ( document ) - Subject request - Continued ART interruption , opinion investigator study adviser , pose unacceptable risk subject . If HIV-1 RNA remain undetectable week 36 , subject offer continue ART close monitoring , conjunction subject 's primary medical provider , long HIV-1 viral rebound occur . ART resumption follow criterion detail . All subject follow total 48 week enrollment .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Adults age 1865 year document HIV1 infection CD4+ Tcell count &gt; 500 cells/mm3 screen On ART minimum 24 month HIV1 RNA plasma level &lt; 50 copies/ml standard assay least 18 month ( single viral load measurement &gt; 50 &lt; 500 copies/ml time period allowable ) . Individuals protease inhibitor NNRTIbased regimen , regimen contain cobicistat must willing switch integraseinhibitorbased regimen ( raltegravir dolutegravir ) prior enrollment . Use systemic corticosteroid , immunosuppressive anticancer , medication consider significant investigator within last 6 month Pregnancy determine positive urine serum betahCG . Participant unwilling use two reliable contraception method ( i.e . condom spermicide , diaphragm spermicide , progestinonly contain intrauterine device ( IUD ) ( eg , Mirena , Implanon , Nuva Ring ) , nonestrogen contain formulation hormonal birth control drug condom ) study duration . Currently breastfeed . History resistance 2 class antiretroviral medication Any medical , psychiatric , social , occupational condition , judge investigator , would interfere evaluation study objective ( severe alcohol drug abuse , dementia ) . Acute chronic hepatitis B C infection indicate presence Hepatitis B surface antigen ( HBsAg ) hepatitis C virus RNA ( HCVRNA ) blood . A history AIDSdefining illness within 3 year prior enrollment . History Bcell lymphoma , include CNS lymphoma CD4 nadir &lt; 200 cells/mm3 History significant coronary artery disease , myocardial infarction , percutaneous coronary intervention placement cardiac stent , family history sudden death age &lt; 50 year . ECG screening show QTc &gt; 450 msec calculate use Fridericia formula either lead V3 V4 , pathological Qwaves ( Qwave &gt; 40 msec depth &gt; 0.40.5 mV ) , evidence ventricular preexcitation syndrome , complete incomplete LBBB RBBB , second third degree heart block , QRS duration &gt; 120 msec , bradycardia define sinus rate &lt; 50 bps Use QTprolonging medication , renal hepatic disease , structural heart disease leave ventricular dysfunction Any symptomatic asymptomatic arrhythmia exclude sinus arrhythmia bradycardia ≥ 50 bps . Laboratory abnormalities parameter list : 1 . Absolute neutrophil count ≤ 1,000 cells/μl 2 . Hemoglobin &lt; 11 gm/dL 3 . Platelet count &lt; 125,000 cells/μl 4 . Alanine Aminotransferase ( ALT ) ≥ 1.25 x ULN 5 . Aspartate Aminotransferase ( AST ) ≥ 1.25 x ULN 6 . Total bilirubin &gt; 1.0 ULN 7 . Creatinine &gt; 1.0 ULN Any vaccination within 14 day prior 3BNC117 administration Receipt therapeutic HIV vaccine past Receipt monoclonal antibody HDAC inhibitor kind past . Participation another clinical study investigational product currently within past 12 week , expect participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Romidepsin</keyword>
	<keyword>3BNC117</keyword>
	<keyword>Broadly neutralize antibody</keyword>
</DOC>